Sign in Subscribe
Dr. Reddy's Laboratories Ltd.

Revolutionary HIV Prevention Tool to be Available at $40 per Year in 120 Low- and Middle-Income Countries Starting in 2027

Strategic Insights

— 1 min read

A groundbreaking partnership between Dr. Reddy's Laboratories, Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI will make the HIV prevention tool, injectable lenacapavir, available at a cost of US$40 per year in 120 low- and middle-income countries starting in 2027. The injection has shown exceptional effectiveness in preventing HIV and will be more accessible than daily oral pre-exposure prophylaxis (PrEP) pills.

Key Takeaways:

  • The HIV prevention tool, injectable lenacapavir, will be available at a cost of US$40 per year in 120 low- and middle-income countries starting in 2027.
  • The partnership aims to make the tool accessible to millions of people who struggle with daily oral PrEP pills.
  • Lenacapavir will be available at a significantly lower cost compared to other HIV prevention options.
  • The partnership includes Dr. Reddy's Laboratories, Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI.
  • The price of the oral course will cost no more than US$17, supporting affordability of the full regimen.
  • Dr. Reddy's is now positioned among the first generic suppliers to come to market, helping establish the competitive landscape essential for long-term success.
  • The deal changes the trajectory for HIV prevention, with a nearly 100% effective tool available at the same time globally by 2027.
  • The agreement is a new model for how innovation reaches those who need it most, and paves the way for the integration of lenacapavir into HIV prevention programs.
  • Unitaid is supporting policy and regulatory processes while working with communities and health systems in early adopter countries to ensure rapid, effective uptake.
  • Gilead's voluntary licenses are an important step forward, but they still do not extend to all countries in need, and Unitaid remains committed to addressing access barriers in countries not covered by the existing agreements.

Statistics:

  • 1.3 million new HIV infections occurred in 2024 (UNAIDS data).
  • 40% reduction in new HIV infections since 2010 (coordinated global efforts).
  • 120 low- and middle-income countries will have access to lenacapavir starting in 2027.
  • US$40 per year, the cost of lenacapavir injection, is significantly lower than other HIV prevention options.
  • US$17, the price of the oral course, supports affordability of the full regimen.

Sources:

  • Dr. Reddy's Laboratories
  • Unitaid
  • The Clinton Health Access Initiative (CHAI)
  • Wits RHI
  • UNAIDS
  • Gilead Sciences

Read more